Average weight reduction in 486 patients
improved from 10.5% at four months to 13.7% at one year on the
Allurion Program
Separate studies with patients on GLP-1 therapy
report significant weight re-gain after discontinuation of drug and
lifestyle intervention program
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to
ending obesity, today announced the publication of a study
demonstrating an average weight reduction of 10.5% at four months
on the Allurion Program, improving to 13.7% at one year. This data
indicate that weight loss can not only be maintained by utilizing
the Allurion Program, but it can also be increased by taking
advantage of the Program’s ongoing virtual guidance and
support.
In the study, 486 patients at a single, high-volume bariatric
center were treated with the Allurion Balloon and assessed monthly
with the Allurion App, Connected Scale, and Health Tracker as part
of the Allurion Program. Over one year, participants were given
virtual access to a team of registered dieticians. A weekly
check-up was conducted for the first month, followed by biweekly
check-ups for the subsequent three months, and monthly check-ups
for the remaining eight months.
"This study is the largest of its kind in Southeast Asia since
the Allurion Balloon was introduced in the region. Results
demonstrate that the swallowable gastric balloon is an effective
solution for patients seeking to lose weight and keep that weight
off,” said Dr. Nik Ritza Kosai, Associate Professor and Consultant
in Gastrointestinal, Obesity and Metabolic Surgery at The National
University of Malaysia and lead author of the study. “Furthermore,
our findings offer strong evidence that the combination of balloon
intervention and one year of virtual supervision can significantly
augment weight loss outcomes.”
Previous studies evaluating GLP-1 drugs indicate that after
discontinuation of the drug and lifestyle intervention program,
patients regained approximately two-thirds of the weight they had
lost.1-3
“While most weight loss is typically observed within the first
four months on the Allurion Program while the balloon is in
residence, the findings from this study demonstrate that, for these
patients, the combination of the Allurion Balloon with a 12-month,
structured, virtual support program significantly contributed to
improved weight loss after balloon passage,” said Dr. Ram Chuttani,
Chief Medical Officer of Allurion. “We believe this study validates
our approach of combining the Allurion Balloon with systematic
evaluation, monitoring, and guidance, offering a more effective
pathway to achieving and maintaining successful weight loss
outcomes.”
Sources: 1. Wilding JPH, Batterham RL, Davies M, et al. Weight
regain and cardiometabolic effects after withdrawal of semaglutide:
The STEP 1 trial extension. Diabetes Obes Metab.
2022;24(8):1553-1564. 2. Aronne LJ, Sattar N, Horn DB, et al.
Continued Treatment With Tirzepatide for Maintenance of Weight
Reduction in Adults With Obesity: The SURMOUNT-4 Randomized
Clinical Trial. JAMA. 2024;331(1):38-48. 3. Rubino D, Abrahamsson
N, Davies M, et al. Effect of Continued Weekly Subcutaneous
Semaglutide vs Placebo on Weight Loss Maintenance in Adults With
Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.
2021;325(14):1414-1425.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is
a weight loss platform that features the Allurion Gastric Balloon,
the world’s first and only swallowable, procedure-less intragastric
balloon for weight loss, and offers access to the Allurion Virtual
Care Suite, including the Allurion Mobile App for consumers,
Allurion Insights for health care providers featuring the Coach
Iris AI Platform, and the Allurion Connected Scale. The Allurion
Virtual Care Suite is also available to providers separately from
the Allurion Program to help customize, monitor and manage weight
loss therapy for patients regardless of their treatment plan:
gastric balloon, surgical, medical or nutritional. The Allurion
Gastric Balloon is an investigational device in the United
States.
For more information about Allurion and the Allurion Virtual
Care Suite, please visit www.allurion.com
Allurion is a trademark of Allurion Technologies, Inc. in the
United States and countries around the world.
Forward-Looking Statements
This press release may contain certain forward-looking
statements within the meaning of the U.S. federal and state
securities laws. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions and
include statements regarding the ability of the Allurion Program,
which combines the Allurion Balloon with ongoing virtual guidance
and support, to improve patient and clinical outcomes, including
outcome improvements over time. Forward-looking statements are
predictions, projections and other statements about future events
that reflect the current beliefs and assumptions of Allurion’s
management based on information currently available to them and, as
a result, are subject to risks and uncertainties. Many factors
could cause actual future results or developments to differ
materially from the forward-looking statements in this
communication, including but not limited to (i) the ability of
Allurion to obtain and maintain regulatory approvals for and
successfully commercialize the Allurion Program, including the
Allurion Balloon and the VCS, (ii) the timing of, and results from,
our clinical studies and trials, (iii) the evolution of the markets
in which Allurion competes, (iv) the ability of Allurion to defend
its intellectual property, (v) the impact of the COVID-19 pandemic,
the Russia and Ukraine war, and the Israel-Hamas conflict on
Allurion’s business, (vi) Allurion’s expectations regarding its
market opportunities, including those for the VCS platform, and
(vii) the risk of economic downturns and a changing regulatory
landscape in the highly competitive industry in which Allurion
operates. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the “Risk Factors” section of
Allurion’s Annual Report on Form 10-K filed on March 26, 2024 (as
subsequently amended) and other documents filed by Allurion from
time to time with the U.S. Securities and Exchange Commission.
These filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Allurion assumes no obligation and does not intend
to update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Allurion
does not give any assurance that it will achieve its
expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240828124974/en/
Global Media Cedric Damour PR Manager +33 7 84 21 02 20
cdamour@allurion.com
Investor Contact Mike Cavanaugh, Investor Relations ICR
Westwicke (617) 877-9641 mike.cavanaugh@westwicke.com
Allurion Technologies (NYSE:ALUR)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Allurion Technologies (NYSE:ALUR)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
